Literature DB >> 20393867

Awareness of Fabry disease among rheumatologists--current status and perspectives.

Rolando Cimaz1, Severine Guillaume, Max J Hilz, Gerd Horneff, Bernhard Manger, J Carter Thorne, Anette Torvin Møller, Nico M Wulffraat, Johannes Roth.   

Abstract

Fabry disease is an inherited disorder of lipid metabolism caused by deficient activity of the lysosomal enzyme α-galactosidase A. Burning peripheral pain with triggered crises of excruciating pain and gastrointestinal dysmotility point to Fabry small fiber neuropathy; angiokeratoma, corneal deposits, and hypohidrosis are other common early manifestations. Progressive dysfunction of the kidneys, heart, and/or brain develops in adulthood. Diagnosis is often delayed which is of great concern, as therapeutic outcomes with enzyme replacement therapy are generally more favorable in early stages of Fabry disease. Results of a survey among 360 rheumatologists and pediatricians clinically managing patients with rheumatologic conditions demonstrate that Fabry manifestations are generally poorly recognized and that awareness of appropriate diagnostic tests is low. To raise awareness about the musculoskeletal aspects of Fabry disease among rheumatologists, the International Musculoskeletal Working Group on Lysosomal Storage Disorders has reviewed the current knowledge. We propose a diagnostic algorithm with burning pain in hands and feet and triggered attacks of excruciating pain as keystones. Evidence of autonomic nerve dysfunction and simple temperature sensitivity testing can provide important diagnostic clues. Multi-systemic involvement should be explored by taking a detailed medical history, including family history, and performing a thorough physical examination and appropriate laboratory workup. Confirmatory tests include the α-Gal A enzyme activity assay (males) and genetic testing (females). We propose that medical specialists use our diagnostic algorithm when evaluating individuals with peripheral neuropathic pain.

Entities:  

Mesh:

Year:  2011        PMID: 20393867     DOI: 10.1007/s10067-010-1445-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  63 in total

1.  Fabry disease: enzymatic diagnosis in dried blood spots on filter paper.

Authors:  N A Chamoles; M Blanco; D Gaggioli
Journal:  Clin Chim Acta       Date:  2001-06       Impact factor: 3.786

2.  Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease.

Authors:  Dominique P Germain; Karelle Benistan; Pierre Boutouyrie; Celine Mutschler
Journal:  Clin Genet       Date:  2005-07       Impact factor: 4.438

Review 3.  Assessment and diagnosis of neuropathic pain.

Authors:  Ralf Baron; Thomas R Tölle
Journal:  Curr Opin Support Palliat Care       Date:  2008-03       Impact factor: 2.302

4.  Onset and progression of the Anderson-Fabry disease related cardiomyopathy.

Authors:  Christoph Kampmann; Ales Linhart; Frank Baehner; Tomas Palecek; Christiane M Wiethoff; Elke Miebach; Catharina Whybra; Andreas Gal; Jan Bultas; Michael Beck
Journal:  Int J Cardiol       Date:  2008-06-24       Impact factor: 4.164

5.  Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.

Authors:  Anette Torvin Møller; Flemming Winther Bach; Ulla Feldt-Rasmussen; Ase Rasmussen; Lis Hasholt; He Lan; Claudia Sommer; Steen Kølvraa; Martin Ballegaard; Troels Staehelin Jensen
Journal:  Pain       Date:  2009-08-07       Impact factor: 6.961

Review 6.  Bilateral femoral head and distal tibial osteonecrosis in a patient with Fabry disease.

Authors:  Yeong-Hau H Lien; Li-Wen Lai
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2005-04

Review 7.  Enzyme replacement therapy for Fabry disease: a systematic review of available evidence.

Authors:  Roland M Schaefer; Anna Tylki-Szymańska; Max J Hilz
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

8.  Joint manifestations of Fabry's disease.

Authors:  S O Paira; S Roverano; J L Iribas; H A Barceló
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

9.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

10.  Association of Fabry's disease with femoral head avascular necrosis.

Authors:  G Ross; F Kuwamura; A Goral
Journal:  Orthopedics       Date:  1993-04       Impact factor: 1.390

View more
  4 in total

Review 1.  Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis.

Authors:  Claire Zar-Kessler; Amel Karaa; Katherine Bustin Sims; Virginia Clarke; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2016-04-15       Impact factor: 4.409

2.  The Influence of Patient-Reported Joint Manifestations on Quality of Life in Fabry Patients.

Authors:  Alexandra Ivleva; Ekaterina Weith; Atul Mehta; Derralynn A Hughes
Journal:  JIMD Rep       Date:  2018-01-30

3.  Frequency of Fabry disease in a juvenile idiopathic arthritis cohort.

Authors:  Luciana Paim-Marques; Amanda Virginia Cavalcante; Islane Verçosa; Paula Carneiro; Marcia Souto-Maior; Erlane Marques; Simone Appenzeller
Journal:  Pediatr Rheumatol Online J       Date:  2021-06-12       Impact factor: 3.054

4.  Significant improvement in Fabry disease podocytopathy after 3 years of treatment with agalsidase beta.

Authors:  Shuichi Ito; Masao Ogura; Koichi Kamei; Kentaro Matsuoka; David G Warnock
Journal:  Pediatr Nephrol       Date:  2016-04-29       Impact factor: 3.651

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.